A股異動 | 北京科鋭(002350.SZ)漲停 兩山產投擬受讓科鋭北方65%股份 公司實控人或變更
格隆匯6月17日丨北京科鋭(002350.SZ)漲停,現報5.63元,暫成交5852萬元,最新總市值30億元。北京科鋭昨日晚間公佈,公司於2020年6月16日接到實際控制人張新育(“轉讓方”)及公司控股股東科鋭北方的通知:張新育與重慶兩山產業投資有限公司(“兩山產投”)簽署了《股權轉讓框架協議》(“框架協議”),兩山產投將依法受讓張新育及科鋭北方其他股東所持科鋭北方約1317.24萬元出資(佔科鋭北方註冊資本的65%),並將通過控制科鋭北方取得上市公司控制權。若上述股份轉讓最終實施完成,公司的實際控制人將發生變更。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.